文献速递慢性肾脏病血液净化与透析肾移植

Renal Lifecycle 试验的原理与设计:评估达格列净对重度慢性肾脏病心肾结局的影响

Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

Renal Lifecycle 是一项国际多中心随机安慰剂对照试验,计划纳入约1500例eGFR≤25 ml/min/1.73 m²、透析或肾移植后eGFR≤45 ml/min/1.73 m²的患者,1:1随机接受达格列净10 mg每日一次或安慰剂。主要终点为心衰住院、全因死亡或(非透析者)肾衰竭的复合终点,事件驱动,预计发生468例主要终点事件后终止。

要点

  • 针对被既往SGLT2抑制剂试验排除的重度CKD、透析和肾移植患者。
  • 主要复合终点包括心衰住院、全因死亡和肾衰竭。
  • 事件驱动设计,检测25%相对风险降低,把握度80%。

核心结论

  • Renal Lifecycle 试验旨在研究达格列净对晚期CKD三个亚组患者肾衰竭、心衰、死亡及安全性的影响。

研究设计与样本

  • 务实、国际、多中心、研究者发起的随机安慰剂对照试验(NCT05374291)。
  • 计划纳入约1500例eGFR≤25 ml/min/1.73 m²、血液透析、腹膜透析或肾移植后eGFR≤45 ml/min/1.73 m²的患者。
  • 1:1随机接受达格列净10 mg每日一次或匹配安慰剂。

主要发现

  • 主要终点为心衰住院、全因死亡或非透析者肾衰竭(开始透析>1个月、接受肾移植或死于肾衰竭)的复合终点。
  • 试验为事件驱动,发生468例首次主要终点事件后终止,把握度80%、α=0.05,假定主要结局年发生率12.5%以检测25%相对风险降低。
  • 次要终点包括主要终点各组分在总人群中的单独分析及复合主要终点在三个亚组中的发生率。
  • 其他探索性终点包括疗效、安全性、耐受性、健康相关生活质量和认知。

临床怎么用

  • 该试验将为达格列净在重度CKD、透析和肾移植患者中的使用提供证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several clinical trials have shown beneficial effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on kidney disease progression and cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) with and without type 2 diabetes mellitus. However, some subgroups of patients with CKD have been excluded from participation in these trials, such as patients with severely impaired kidney function, patients on dialysis and kidney transplant recipients. METHODS: The Renal Lifecycle trial (NCT05374291) is a pragmatic, international, multicentre, investigator-initiated, randomized, placebo-controlled clinical trial planned to enrol ≈1500 patients with an estimated glomerular filtration rate (eGFR) ≤25 ml/min/1.73 m2, on haemodialysis or peritoneal dialysis or after a kidney transplant and an eGFR ≤45 ml/min/1.73 m2, who will be randomized 1:1 to receive either dapagliflozin 10 mg once daily or matching placebo. RESULTS: The primary endpoint is a composite of heart failure hospitalization, all-cause mortality or, for those not on dialysis, kidney failure (start of dialysis >1 month, receiving a kidney transplant or death due to kidney failure). The trial is event driven, indicating that it will end after 468 first primary endpoint events have occurred, with a power of 80% and an α of 0.05 to detect a 25% relative risk reduction assuming an annual 12.5% incidence of the primary outcome. The secondary endpoints include a separate analysis of the incidence of each component of the primary endpoint in the overall trial population as well as the incidence of the combined primary endpoint in each of the three subgroups of patients. Other (exploratory) endpoints are efficacy, safety, tolerability, health-related quality of life and cognition. CONCLUSION: The Renal Lifecycle trial aims to investigate the effects of the SGLT2 inhibitor dapagliflozin compared with placebo on the incidence of kidney failure, heart failure, mortality and safety in three subgroups of patients with advanced CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Bakker WM, Heerspink HJL, Berger SP, et al. Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease. Nephrol Dial Transplant. 2025. PMID: 40053493. doi:10.1093/ndt/gfaf046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。